Suppr超能文献

100例慢性肾脏病患者中因血管紧张素阻断导致的迟发性肾衰竭(LORFFAB)

Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients.

作者信息

Onuigbo Macaulay A C, Onuigbo Nnonyelum T C

机构信息

Mayo Clinic College of Medicine, Rochester, MN, USA.

出版信息

Int Urol Nephrol. 2008;40(1):233-9. doi: 10.1007/s11255-007-9299-2. Epub 2008 Jan 15.

Abstract

INTRODUCTION

Notwithstanding proven renoprotection from RAAS blockade (AB) with ACE inhibitors and ARBs, and despite increasing utilization of AB in the US, we have continued to experience a CKD/ESRD epidemic. Given concerns for iatrogenic CKD/ESRD, we designed a prospective study to analyze the course of eGFR following withdrawal of AB in such patients.

PATIENTS

Between September 2002 and February 2005, all consecutive CKD patients on AB presenting with >25% increase in baseline serum creatinine were enrolled. eGFR following withdrawal of AB was monitored. The main outcome measures were serum creatinine, MDRD eGFR, and UA/Cr.

RESULTS

100 Caucasians, M:F=52:48, mean age 71.5 years were enrolled. Mean follow up was 26 months. Sixteen patients progressed to ESRD, of whom seven died. In 74, eGFR improved from 23.9+/-9 (7-47) to 39.2+/-15.4 (17-89) ml/min/1.73 m(2) BSA, 26.5 (3-46) months after stopping AB (P=0.001). The majority of the cohort, 95 patients, had known risk factors: 26 with RAS, 12 hypovolemia, 11 sepsis, 10 NSAIDs/cox II inhibitor use/abuse, 7 CIN, 2 congestive heart failure, 2 obstructive uropathy, and 27 with other medical and surgical causes, including malignancies, postoperative states, and infections. In the 26 with RAS, 5 with higher baseline creatinine -2.1+/-0.6 versus 1.5+/-0.4 mg/dL, P=0.013, progressed to ESRD; 4/5 ESRD patients died after 6.3 months. The remaining five patients (one male and four females), mean age 68 (44-83) years, demonstrated sustained improved eGFR with discontinuation (four) or reduction (one) of RAAS blockade, despite normal renal arteries and the absence of known traditional risk factors. UA/Cr generally increased following withdrawal of AB.

CONCLUSIONS

Worsening azotemia in older susceptible CKD patients on AB, often but not always associated with known precipitating risk factors, remains under-recognized. Sustained improved eGFR often follows the discontinuation of AB. The practising physician should be well aware of these syndromes. Our observations call for further study.

摘要

引言

尽管已证实使用血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)阻断肾素-血管紧张素-醛固酮系统(RAAS)具有肾脏保护作用,且在美国使用这类药物的情况日益增多,但我们仍持续面临慢性肾脏病(CKD)/终末期肾病(ESRD)的流行。鉴于对医源性CKD/ESRD的担忧,我们设计了一项前瞻性研究,以分析此类患者停用RAAS阻断剂后估算肾小球滤过率(eGFR)的变化过程。

患者

在2002年9月至2005年2月期间,纳入所有连续使用RAAS阻断剂且基线血清肌酐升高>25%的CKD患者。监测停用RAAS阻断剂后的eGFR。主要观察指标为血清肌酐、简化肾脏病膳食改良试验(MDRD)估算的肾小球滤过率以及尿酸/肌酐比值(UA/Cr)。

结果

共纳入100名白种人,男性与女性比例为52:48,平均年龄71.5岁。平均随访时间为26个月。16例患者进展为ESRD,其中7例死亡。74例患者的eGFR从23.9±9(7 - 47)ml/min/1.73m²体表面积改善至39.2±15.4(17 - 89)ml/min/1.73m²体表面积,在停用RAAS阻断剂26.5(3 - 46)个月后出现改善(P = 0.001)。该队列中的大多数患者(95例)具有已知的危险因素:26例存在肾素-血管紧张素系统(RAS)异常、12例血容量不足、11例脓毒症、10例使用非甾体抗炎药/环氧化酶-2(COX-2)抑制剂/滥用此类药物、7例对比剂肾病(CIN)、2例充血性心力衰竭、2例梗阻性尿路病以及27例因其他内科和外科病因,包括恶性肿瘤、术后状态及感染。在26例存在RAS异常的患者中,5例基线肌酐水平较高(2.1±0.6对比1.5±0.4mg/dL,P = 0.013),进展为ESRD;5例ESRD患者中有4例在6.3个月后死亡。其余5例患者(1例男性和4例女性),平均年龄68(44 - 83)岁,尽管肾动脉正常且无已知传统危险因素,但停用(4例)或减少(1例)RAAS阻断剂后,eGFR持续改善。停用RAAS阻断剂后,UA/Cr通常升高。

结论

在使用RAAS阻断剂的老年易感CKD患者中,氮质血症恶化情况往往(但并非总是)与已知的促发危险因素相关,目前仍未得到充分认识。停用RAAS阻断剂后,eGFR常常持续改善。执业医师应充分了解这些综合征。我们的观察结果需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验